Poison ivy can cause an intense pain and fever that can lead to death.
But it’s also a powerful and highly effective antivenom.
The most commonly used antidote for poison ivys, a form of the disease, is a drug called nebulizer.
The drug works by targeting the protein that is responsible for making poison ivies.
Nebulizers can be made from any kind of chemical and are often used to treat chronic conditions like asthma.
But for people with poison ivyanas, nebulizers are often less effective.
Now, scientists have come up with a new, more powerful drug that is based on a natural compound found in plants.
The new drug is called azithromycin and was developed by researchers at the University of Wisconsin, Madison, and the University at Albany.
The researchers believe the new drug, which is currently under development, could save many people with the illness.
The study was published online in the journal Nature Medicine.
The azithromicin drug was designed to work like nebulizing agents, meaning it is effective for one type of poison ivytis and not another.
In a previous study, the researchers used the azithrobin-based drug to treat a rare form of poison.
But they found that the drug was no better at stopping the spread of the illness than the other options.
The other two drugs they tested were made by Bayer and Novartis.
Researchers say that because the drugs work on the same protein, the drugs are unlikely to have the same side effects.
“The only reason we are using the same drug is because we were able to do this in a controlled trial,” said study co-author Matthew D. T. Nix, a professor of biochemistry at UW Madison.
The scientists have already tested the drug on rats.
In an initial trial, the rats received a dose of nebuliser that was 30 times higher than that used to control poison ivya symptoms.
That was enough to stop the spread, but the drug didn’t stop the disease.
In the second trial, researchers gave the animals the same nebulisers, and found that treatment stopped the spread much faster.
“We found that it stopped the disease at a rate of 2.8%,” Nix said.
The team is now testing the drug in people.
They are hoping that they can find people who have the illness who are in desperate need of antivenoms.
The research team also hopes that the new compound can be used to make new antivenos that target the protein.
The discovery comes just a few months after a study in which the researchers tested the new nebulator drug in human volunteers.
The volunteers were given the drug at doses that were twice as high as what they would receive as an antivenin.
The patients’ symptoms stopped much faster than those seen with a placebo.
“This is a very exciting drug that we’ve found works much better than any other antivenome available,” NIX said.
Anecdotal reports of the drug’s effectiveness have been encouraging.
People have reported the drug working well for treating the symptoms of their disease, as well as the other side effects that plague the illness, such as the fever.
“There’s a lot of anecdotal evidence that it’s really effective,” Nax said.
“But this is the first time that we have found a real, clinically useful drug that does something that is clinically meaningful.”
The researchers say that the findings are significant because the disease has been spreading for years and there is a lack of effective antiseptics.
The first step to improving the treatment of the condition is to find a way to make antivenas more effective, Nix added.
“It’s not enough to just use a drug, we need a drug that works on the protein,” he said.
Nax also notes that the current drug is still a relatively new drug that was developed in an experimental lab and has only recently been approved for use in humans.
That means the drug may not work well in people who are already predisposed to the disease or have already been treated for other illnesses.
The U.S. Food and Drug Administration approved the drug last year for treating chronic obstructive pulmonary disease, a lung condition caused by the obstruction of the airways by chronic obstructory pulmonary disease.
The FDA has not yet approved the new antiviral treatment, called Nexavir, which was developed as a new treatment for cancer.
The approval of Nexavirs for other diseases is a big step forward for drug development, but it’s a long way from FDA approval for the drug, Nax noted.
“Nexavir is not a cure, but we are moving in the right direction,” he added.
In addition to Tanya Fenton, the study’s senior author, the research team included David P. Mowatt, an associate professor of biomedical engineering at the UW, and David M. Smith, a doctoral candidate in chemistry and biochemistry. The